PMID- 38042384 OWN - NLM STAT- MEDLINE DCOM- 20240101 LR - 20240102 IS - 1872-7573 (Electronic) IS - 0378-8741 (Linking) VI - 321 DP - 2024 Mar 1 TI - Leaves and pseudostems extract of Curcuma longa attenuates immunoglobulin E/bovine serum albumin-stimulated bone marrow-derived cultured mast cell activation and passive cutaneous anaphylaxis in BALB/c mice. PG - 117529 LID - S0378-8741(23)01399-5 [pii] LID - 10.1016/j.jep.2023.117529 [doi] AB - ETHNOPHARMACOLOGICAL RELEVANCE: Curcuma longa, known as turmeric, is an herbaceous perennial plant belonging to the genus Curcuma. It is dispersed throughout tropical and subtropical regions worldwide. Since ancient times, turmeric has been used as an ethnomedicinal plant in the Ayurvedic system, particularly in Asian countries. Rhizomes of turmeric possess several pharmacological properties that give high value as a medicinal remedy for treating a range of conditions, including inflammation, pain, allergies, and digestive issues. Moreover, turmeric leaves and pseudostems also contain a variety of health-enhancing secondary metabolites, such as curcumin, flavonoids, and other phenolic compounds, which exhibit anti-inflammatory, antitumor, antibacterial, and antioxidant properties. AIM OF THE STUDY: Allergic diseases are a group of immune-mediated disorders mainly caused by an immunoglobulin E (IgE)-dependent immunological response to an innocuous allergen. Therefore, this study aimed to investigate the effect of leaves and pseudostems extract of turmeric (TLSWE-8510) on IgE/bovine serum albumin (BSA)-stimulated allergic responses in mouse bone marrow-derived cultured mast cells (BMCMCs) and passive cutaneous anaphylaxis (PCA) in BALB/c mice. MATERIALS AND METHODS: The effect of TLSWE-8510 on mast cell degranulation has been evaluated by investigating the release of beta-hexosaminidase and histamine in IgE/BSA-stimulated BMCMCs. Additionally, anti-allergic properties of TLSWE-8510 on IgE/BSA-stimulated BMCMCs were investigated using suppression of nuclear factor-kappa B (NF-kappaB), and spleen tyrosine kinase (Syk)-linker for T-cell activation (LAT)-extracellular-signal-regulated kinase (ERK)-GRB2 associated binding protein 2 (Gab2) signaling pathway and downregulation of allergy-related cytokines and chemokines expression. Furthermore, in vivo, studies were conducted using IgE-mediated PCA in BALB/c mice. RESULTS: TLSWE-8510 treatment significantly inhibited the degranulation of IgE/BSA-stimulated BMCMCs by inhibiting the release of beta-hexosaminidase and histamine dose-dependently. Additionally, TLSWE-8510 reduced the expression of high-affinity IgE receptors (Fc epsilon receptor I-FcepsilonRI) on the surface of BMCMCs and the binding of IgE to FcepsilonRI. Besides, the expression of cytokines and chemokines is triggered by IgE/BSA stimulation via activating the allergy-related signaling pathways. TLSWE-8510 dose-dependently downregulated the mRNA expression and the production of allergy-related cytokines (interleukin (IL)-1beta, IL-3, IL-4, IL-5, IL-6, IL-13, tumor necrosis factor (TNF)-alpha, and interferon (IFN)-gamma), and chemokines (thymus and activation-regulated chemokine (TARC), and regulated upon activation, normal T cell expressed and secreted (RANTES)) by regulating the phosphorylation of downstream signaling molecules, NF-kappaB, and Syk, LAT, ERK and Gab2 in IgE/BSA-stimulated BMCMCs. Moreover, PCA reaction in IgE/BSA-stimulated BALB/c mice ears was effectively decreased by TLSWE-8510 treatment in a dose-dependent manner. CONCLUSIONS: These results collectively demonstrated that TLSWE-8510 suppressed mast cell degranulation by inhibiting the release of chemical mediators related to allergies. TLSWE-8510 downregulated the allergy-related cytokines and chemokines expression and phosphorylation of downstream signaling molecules in IgE/BSA-stimulated BMCMCs. Furthermore, in vivo studies with IgE-mediated PCA reaction in the BALB/c mice ears were attenuated by TLSWE-8510 treatment. These findings revealed that TLSWE-8510 has the potential as a therapeutic agent for the treatment of allergic diseases. CI - Copyright (c) 2023. Published by Elsevier B.V. FAU - Jayasinghe, Arachchige Maheshika Kumari AU - Jayasinghe AMK AD - Department of Food Technology and Nutrition, Chonnam National University, Yeosu, 59626, Republic of Korea. Electronic address: 218385@jnu.ac.kr. FAU - Kirindage, Kirinde Gedara Isuru Sandanuwan AU - Kirindage KGIS AD - Department of Food Technology and Nutrition, Chonnam National University, Yeosu, 59626, Republic of Korea. Electronic address: 218388@jnu.ac.kr. FAU - Kim, Sun-Hyung AU - Kim SH AD - French Korea Aromatics Co., Ltd., Yongin-si, Gyeonggi-do, Republic of Korea. Electronic address: sunhyung@fka.co.kr. FAU - Lee, Seok AU - Lee S AD - French Korea Aromatics Co., Ltd., Yongin-si, Gyeonggi-do, Republic of Korea. Electronic address: seok.lee@fka.co.kr. FAU - Kim, Kil-Nam AU - Kim KN AD - Gwangju Center, Korea Basic Science Institute (KBSI), Gwangju, 61751, Republic of Korea. Electronic address: knkim@kbsi.re.kr. FAU - Kim, Eun-A AU - Kim EA AD - Jeju International Marine Science Center for Research & Education, Korea Institute of Ocean Science & Technology (KIOST), Jeju, 63349, Republic of Korea. Electronic address: euna0718@kiost.ac.kr. FAU - Heo, Soo-Jin AU - Heo SJ AD - Jeju International Marine Science Center for Research & Education, Korea Institute of Ocean Science & Technology (KIOST), Jeju, 63349, Republic of Korea. Electronic address: sjheo@kiost.ac.kr. FAU - Ahn, Ginnae AU - Ahn G AD - Department of Food Technology and Nutrition, Chonnam National University, Yeosu, 59626, Republic of Korea; Department of Marine Bio-Food Sciences, Chonnam National University, Yeosu, 59626, Republic of Korea. Electronic address: gnahn@jnu.ac.kr. LA - eng PT - Journal Article DEP - 20231130 PL - Ireland TA - J Ethnopharmacol JT - Journal of ethnopharmacology JID - 7903310 RN - 37341-29-0 (Immunoglobulin E) RN - 27432CM55Q (Serum Albumin, Bovine) RN - 0 (NF-kappa B) RN - 820484N8I3 (Histamine) RN - 0 (Cytokines) RN - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases) RN - 0 (Tumor Necrosis Factor-alpha) RN - EC 3.2.1.52 (beta-N-Acetylhexosaminidases) RN - 0 (Chemokines) SB - IM MH - Mice MH - Animals MH - Immunoglobulin E MH - Curcuma MH - Serum Albumin, Bovine MH - NF-kappa B/metabolism MH - Histamine/metabolism MH - Mast Cells MH - Passive Cutaneous Anaphylaxis MH - Mice, Inbred BALB C MH - Bone Marrow MH - *Hypersensitivity/drug therapy MH - Cytokines/metabolism MH - Extracellular Signal-Regulated MAP Kinases/metabolism MH - Tumor Necrosis Factor-alpha/metabolism MH - beta-N-Acetylhexosaminidases/metabolism MH - Chemokines/metabolism MH - *Anaphylaxis MH - Cell Degranulation OTO - NOTNLM OT - Anti-allergic effect OT - Bone marrow-derived cultured-mast cells OT - Curcuma longa OT - Immunoglobulin E OT - Passive cutaneous anaphylaxis COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/12/03 00:42 MHDA- 2024/01/02 11:45 CRDT- 2023/12/02 19:29 PHST- 2023/10/12 00:00 [received] PHST- 2023/11/24 00:00 [revised] PHST- 2023/11/27 00:00 [accepted] PHST- 2024/01/02 11:45 [medline] PHST- 2023/12/03 00:42 [pubmed] PHST- 2023/12/02 19:29 [entrez] AID - S0378-8741(23)01399-5 [pii] AID - 10.1016/j.jep.2023.117529 [doi] PST - ppublish SO - J Ethnopharmacol. 2024 Mar 1;321:117529. doi: 10.1016/j.jep.2023.117529. Epub 2023 Nov 30.